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The activity of endothelial nitric oxide synthase
(eNOS) is subject to complex transcriptional and post-
translational regulation including the association
with several proteins and variations in subcellular
distribution. In the present study we describe a trans-
genic mouse model expressing eNOS fused to green
fluorescent protein (GFP), which allows the study of
localization and regulation of eNOS expression. We
tested the functionality of eNOS in the eNOS-GFP
mice. Expression of eNOS was restricted to the endo-
thelial lining of blood vessels in various tissues tested,
without appreciable expression in non-endothelial
cells. Activity of the enzyme was confirmed by assay-
ing the conversion of L-arginine to L-citrulline. NO
production in isolated vessels was increased in trans-
genic mice when compared to non-transgenic control
animals (4.88  0.59 and 2.48  0.47 mol/L NO,
respectively, P < 0.005). Both the mean aortic pres-
sure and the pulmonary artery pressure were reduced
in eNOS-GFP mice (both 30%, P < 0.05). Plasma
cholesterol levels were also slightly reduced (20%,
P < 0.05). In conclusion, eNOS-GFP mice express
functional eNOS and provide a unique model to study
regulation of eNOS activity or eNOS-mediated vascular
events, including response to ischemia, response to
differences in shear stress, angiogenesis and vasculo-
genesis, and to study the subcellular distribution in
relation with functional responses to these events.
(Am J Pathol 2003, 163:1677–1686)
In endothelial cells, nitric oxide (NO) is generated by the
enzyme endothelial nitric oxide synthase (eNOS) via the
conversion of L-arginine to L-citrulline. NO produced by
eNOS affects a number of biological processes in the
vessel wall. It is important for the regulation of blood
pressure and plays an important role in the aggregation
of blood platelets, adhesion of leukocytes to the vessel
wall, and migration of vascular smooth muscle cells.1 A
decrease in NO availability is one of the hallmarks of
endothelial dysfunction, which can occur in a number of
cardiovascular disorders, including hypertension, heart
failure, diabetes, and atherosclerosis.2 It has been shown
in animal models that a decrease in eNOS activity results
in accelerated atherosclerosis.3,4 Conversely, stimulation
of eNOS activity by statin treatment has been implicated
in the protective actions of these drugs.5–7
For these reasons, the regulation of eNOS activity is
considered to be of major physiological and pathophys-
iological importance. Although eNOS was originally
termed endothelial constitutive NOS (ecNOS),8–10 sev-
eral laboratories have found that its protein expression
and enzymatic activity is under tight regulation.10–13 In
addition to regulation at the transcriptional level, protein
activity is controlled in several ways. Regulatory pro-
cesses include N-myristoylation and cysteine palmitoyl-
ation, serine/threonine phosphorylation, and protein-pro-
tein interactions. These events affect the intracellular
localization of eNOS which might influence its enzymatic
activity. Normally, eNOS is localized in two subcellular
compartments: the Golgi complex and the plasma mem-
brane.14 Although it has been suggested that transloca-
tion between these two compartments is important in the
regulation of the enzymatic activity, it has been demon-
strated that eNOS in both pools can be phosphorylated
and activated.14 In vitro studies of cells transfected with
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eNOS cDNA fused to DNA encoding green fluorescent
protein (GFP) have provided valuable information of
eNOS localization and regulation. However, to date such
studies have not been performed in vivo. Consequently,
we developed a transgenic mouse model in which an
eNOS-GFP fusion protein is expressed. The results indi-
cate that the eNOS fusion protein is functionally intact.
These eNOS-GFPtg mice can be used to study vascular
reactions in which eNOS is involved, including angiogen-
esis or response to variations in shear stress.
Materials and Methods
Generation of eNOS-GFP Transgenic Mice
A genomic DNA fragment was isolated from a home-made
human cosmid library. It included 6 kb of 5 sequence, the
complete eNOS gene, and 3 kb of 3 sequence. At the
STOP codon of the eNOS gene, a linker was introduced that
allowed the in-frame insertion of a BamHI-NotI DNA frag-
ment encoding eGFP which was derived from the
pEGFP-N1 plasmid (BD Biosciences Clontech, Palo Alto,
CA). Fertilized oocytes from FVB mice were microinjected
with a solution of 1–2 g/ml in 8 mmol/L Tris-HCl and 0.1
mmol/L ethylenediaminetetraacetate (EDTA) and trans-
planted into the oviducts of pseudopregnant B10xCBA
mice. Founder mice and offspring were genotyped by PCR
on DNA isolated from tail biopsies. Primers used were:
5-GTCCTGCAGACCGTGCAGC-3 (sense) and 5-GGCT-
GTTGGTGTCTGAGCCG-3 (antisense). Mice were back-
crossed to C57Bl6 for at least five generations (96%
C57Bl6). Transgenic mice used in the present study were
hemizygous. All animal experiments were performed in
compliance with institutional and national guidelines.
Immunohistochemistry, Fluorescence
Microscopy, Confocal Microscopy
Immunohistochemistry experiments were performed ac-
cording to Bakker et al15 on 7-m paraffin sections. The
antibodies used were raised against the carboxy termi-
nus of eNOS (Santa Cruz Biotechnology Inc., Santa Cruz,
CA; catalog number sc-654). For confocal microscopy,
mice were sacrificed using an overdose of isoflurane
(1-chloro-2,2,2-trifluoroethyl-difluoromethyl-ether). Sub-
sequently, in situ perfusion fixation was performed by
flushing 20 ml PBS through a cardiac puncture followed
by 20 ml 4% (v/v) paraformaldehyde in PBS. The com-
mon carotid arteries were then harvested, fixed in 4%
paraformaldehyde in PBS at 4°C, and mounted in
Vectashield (Vector Laboratories, Inc., Burlingame, CA)
between glass slides. Samples were examined under a
Zeiss LSM inverted laser-scanning confocal fluorescence
microscope. Images of GFP fluorescence were acquired
after excitation with a 488-nm argon laser and after filter-
ing the fluorescence with a 500- to 550-nm bandpass
barrier filter. The thickness of the optical slice images was
0.6 m.
Western Blotting
Western blotting experiments were performed as
described previously.16 The antibodies used were di-
rected against human eNOS or human eNOS phos-
phorylated at Ser-1177, both obtained from Santa Cruz
Biotechnology, Inc. (catalog numbers sc-654 and sc-
12972, respectively).
eNOS Enzyme Activity and Nitric Oxide
Measurements
eNOS activity was measured in the L-arginine to L-citrul-
line conversion assay using a nitric oxide synthase assay
kit (Calbiochem, La Jolla, CA; catalog number 482700)
as described previously.16 For NO measurements, mice
were anesthetized with 0.2 ml i.p. sodium pentobarbital
(Apharmo BV, Arnhem, The Netherlands) and intracardi-
ally perfused with 10 ml Krebs Henseleit buffer solution
(118 mmol/L NaCl, 4.7 mmol/L KCl, 3.0 mmol/L CaCl2, 1.2
mmol/L KH2PO4, 1.2 mmol/L MgSO4, 25 mmol/L
NaHCO3, 0.5 mmol/L EDTA, 10 mmol/L D-glucose, and
0.1 mmol/L L-arginine, equilibrated with 95% air and 5%
CO2 at room temperature resulting in a pH of 7.4). The
aorta was dissected and in situ cannulated with two metal
cannulas, proximal at the level of aortic arch and distal at
the level of the diaphragm. The cannulas were connected
to a home-made device keeping the vessel at its original
length. Next, the vessel was transported to the set-up,
where the cannulas were fixed to two holders. The two
holders were placed in a chamber filled with Krebs
buffer. The cannula at the proximal end of the vessel was
connected to Tygon tubing coming out of a reservoir with
Krebs buffer. Between the reservoir and the cannula, a
flow pump (Watson Marlow, Falmouth, Cornwall, UK) and
an infusion pump (Perfusor VI; B.Braun, Melsungen, Ger-
many) were positioned. The settings of the pump were
adjusted to perfuse the aorta with a constant flow of 10
ml/min, measured by an electromagnetic flow sensor.
This value was based on measurements of the cardiac
output of our mice with a clinical Doppler device (Pro-
sound 4000, Aloka, Japan) or by a transit-time flow probe
(see below). Next, the aorta vessel was equilibrated by
perfusing it for 30 minutes. During that period the exper-
imental set-up was switched to its calibration state and
the NO sensor was calibrated by infusing known NO
concentrations through a tube mounted in parallel to the
vessel (0.1 to 30 mol/L). Then, L-arginine (0.1 mol/L) in
Krebs buffer was added to the perfusate via the infusion
pump. The NO-sensitive electrode was positioned at the
distal end of the aorta, to measure the NO production by
the vessel. The electrode was connected to an NO mea-
surement system (Iso-NO mark II; World Precision Instru-
ments, Sarasota, FL). All data, including temperature,
pressure drop, flow and NO measurements were stored
in a PC equipped with an analog-digital converter and
analysis software (Advanced Technology CODAS; Dataq
Instruments, Akron, OH).
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Hemodynamics and Heart Weights
Hemodynamic measurements were performed as de-
scribed.16 Shortly, blood pressure measurements were
performed on mice anesthetized with ketamine (100
mg/kg ip) and xylazine (20 mg/kg ip), intubated and
ventilated with a mixture of O2 and N2 (1/2 v/v). A flame
stretched PE 50 polyethylene catheter was inserted into
the right carotid artery and advanced into the aortic arch
for measurement of aortic pressure and connected to a
pressure transducer (B.Braun). For infusion of L-NAME, a
second catheter was introduced into the right external
jugular vein and advanced into the superior caval vein.
After thoracotomy through the second right intercostal
space, the ascending aorta was exposed and a transit-
time flow probe (ID 1.5 mm; Transonics systems T206,
Ithaca, NY) was placed around the aorta for measuring
aorta flow. Ten minutes after a second intraperitoneal
bolus of 100 mg/kg ketamine and 20 mg/kg xylazine,
baseline recordings were obtained. Then, a continuous
10-minute intravenous infusion of L-NAME (100 mg/kg)
was started and measurements were continued until 10
minutes after completion of the infusion. For the measure-
ments of pulmonary artery pressure, the second left in-
tercostal space was opened and a 30G needle con-
nected to a PE 10 polyethylene catheter was directly
inserted into the pulmonary artery. Hemodynamic data
were recorded and digitized using an on-line 4 channel
data acquisition program (Advanced Technology CO-
DAS; Dataq Instruments). Ten consecutive beats were
selected for determination of heart rate, aortic and pul-
monary artery pressures, and aortic blood flow. For de-
termination of ventricular weights the heart was removed
and the ventricles were separated from the atria, the
aorta, and the pulmonary artery. The right ventricle (free
wall) was carefully separated from the left ventricle (in-
cluding septum) and the right and left ventricle were
weighed on a microbalance (Sartorius AG Go¨ttingen,
Germany). For the measurements of dry weights, tissue
fluids were removed by lyophilization.
Cholesterol and Lipoprotein Analysis
Blood was collected by orbital puncture after an over-
night fast. Plasma from 6 to 10 mice was pooled and
subjected to gel filtration analysis on two HR10/30 FPLC
columns in tandem (Superdex 200 and Superose 6, both
prepgrade; Pharmacia AB, Uppsala, Sweden).17 Choles-
terol concentrations were measured with the free choles-
terol C kit (WAKO, Neuss, Germany) after hydrolysis of
cholesterol esters with cholesterol esterase from Candida
cylindracea.
Data Analysis
Analysis of data were performed using two-way or one-
way analysis of variance followed by Scheffe´’s test, as
appropriate. Statistical significance was accepted when
P  0.05 (two-tailed). Data are presented as mean 
SEM.
Results
eNOS-GFP Transgenic Mice
We aimed to create mice transgenic for human eNOS, in
which the expression resembled that of the endogenous
gene as much as possible, both with respect to the
expression pattern as well as the regulation. Therefore,
we used a DNA fragment to generate transgenic mice
that comprised the complete human eNOS genomic se-
quence, including the natural promoter. This fragment
was isolated from a human cosmid library. In addition to
the eNOS gene, the DNA fragment contained 6 kb of 5
sequence, including the endothelial enhancer sequence
identified by Laumonnier et al,18 and 3 kb of 3 se-
quence. At the STOP codon of the eNOS gene, a DNA
fragment encoding enhanced GFP was inserted in frame
with the eNOS gene, to obtain a DNA construct encoding
an eNOS-GFP fusion protein. This fragment (Figure 1a)
was used for the generation of eNOS-GFP transgenic
(eNOS-GFPtg) mice. Figure 1b shows sections from
mouse aorta, taken from eNOS-GFPtg mice or wild-type
littermates (controls). Immunohistochemistry studies on
these sections using an antibody directed against human
eNOS revealed a strong staining of the endothelial layer
of the aorta in the eNOS-GFPtg mice, while there was no
staining in the media of the aorta (Figure 1b, lower left
panel). Sections from non-transgenic controls showed
virtually no staining (Figure 1b, upper left panel). Inspec-
tion with fluorescence microscopy showed a strong fluo-
rescent signal in the endothelial layer of the aorta from
eNOS-GFPtg mice (Figure 1b, lower right panel), which is
much higher than the autofluorescence from the elastic
lamellae that is present in both eNOS-GFPtg mice and in
wild-type controls (Figure 1b, upper right panel). The
subcellular localization was studied by confocal micros-
copy in the carotid artery (Figure 1c). The expression
pattern exactly matches the sites where eNOS is known
to be primarily located: in the Golgi complex and at the
plasma membrane. We performed Western blotting ex-
periments with aorta and lung tissue from eNOS-GFPtg
mice and non-transgenic controls (Figure 1d). Using an
antibody directed against human eNOS, both the endog-
enous murine eNOS is detected, caused by cross-reac-
tivity of the antibody, as well as the eNOS-GFP fusion
protein, which has a slightly higher molecular mass
caused by the GFP moiety (approximately 130 kd and
155 kd, respectively; Figure 1d, left panels). In addition,
we used an antibody that recognizes eNOS that is phos-
phorylated on serine 1177 (P-eNOS), which is the acti-
vated form of the enzyme. P-eNOS-GFP is present in both
aorta and lung tissue from eNOS-GFPtg mice (Figure 1d,
right panels). To determine whether the expressed
eNOS-GFP fusion protein is catalytically active, enzy-
matic activity was measured in aorta and lung tissue from
eNOS-GFPtg mice and non-transgenic controls. As
shown in Figure 1e, the transgenic mice show an in-
crease in eNOS activity of approximately 35-fold in aorta
and 27-fold in lung tissue. In addition, NO production was
measured in isolated vessels ex vivo, using an NO sensor.
Aortas from eNOS-GFP transgenic mice showed an in-
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creased NO production compared with aortas from con-
trol mice (Figure 1f). The data could be described by a
first order kinetic reaction, which was confirmed by a
Lineweaver-Burke transformation (data not shown).
Localization of eNOS-GFP
To investigate the cell specificity of the expression of the
transgene, sections from organs of eNOS-GFPtg mice
were inspected by immunohistochemistry using an anti-
body directed against human eNOS (Figure 2). eNOS
immunoreactivity was detected in small blood vessels in
the heart (Figure 2a), in the sinusoids in the liver (Figure
2b), in the peritubular capillaries, and in the endothelial
cells in the glomeruli in the kidney (Figure 2c) and in the
capillary sinusoids in the adrenal (Figure 2d). eNOS pro-
tein was not found in the parenchymal cells of these
organs. Sections from non-transgenic controls showed
no immunoreactivity (not shown). This expression pattern
was confirmed by fluorescence microscopy. Figure 3
shows micrographs from heart (Figure 3, a and b), liver
(Figure 3, c and d), kidney (Figure 3, e and f), and
Figure 1. Transgenic mice expressing eNOS-GFP. a: The DNA construct used for the generation of eNOS-GFPtg mice consisted of the complete eNOS gene in
which an eGFP encoding cassette was cloned in frame at the position of the eNOS STOP codon. The natural flanking sequences of the eNOS gene were left intact.
b: Sections of aorta from control mice or eNOS-GFP transgenic mice, inspected with immunohistochemistry using an antibody directed against human eNOS (left
panels) or by fluorescent microscopy (right panels). Original magnifications, 630. c: Green fluorescence in endothelial cells from an intact carotid artery
inspected with confocal microscopy. Double arrowheads indicate fluorescence at the position of the plasma membrane; the filled arrow indicates fluorescence
at the position of the Golgi complex. The open arrow indicates the cell nucleus. Scale bar, 10 m. d: Immunoblotting of aorta (upper panels) or lung (lower
panels) homogenates with antibodies directed against human eNOS (left panels), which show cross-reactivity with endogenous mouse eNOS, or antibodies
directed against phosphorylated Ser-1177 from human eNOS (right panels). e: eNOS activity measured in aorta or lung homogenates by the L-arginine to
L-citrulline conversion assay. n  9. *, P  0.001. f: NO production in isolated aortas measured with an NO-sensitive electrode. n  11 (C), n  8 (Tg). *, P 
0.005. C, control mice; Tg, eNOS-GFP transgenic mice.
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adrenal gland (Figure 3, g and h). The lining of the larger
vessels was clearly fluorescent (Figure 3c). A dense cap-
illary network was fluorescent in the heart, surrounding
the cardiomyocytes, and in the adrenal. The sinusoids in
the liver, as well as the peritubular capillaries in the
kidney showed a positive signal, just like the capillaries of
the glomeruli in the kidney. The parenchymal cells of
none of these organs showed appreciable expression. In
sections from non-transgenic controls, no fluorescent sig-
nal was detected (not shown).
Hemodynamic Properties of eNOS-GFPtg Mice
We performed hemodynamic measurements in eNOS-
GFPtg mice compared to non-transgenic control mice.
This was done to establish the functional activity of the
eNOS-GFP fusion protein, as eNOS-derived NO is an
important modulator of vascular tone. As shown in Figure
4a, the mean aortic pressure (MAP) was decreased in
eNOS-GFP-expressing mice compared to wild-type litter-
mates by approximately 29%. Treatment with the NO
synthase-inhibitor NG nitro-L-arginine methyl ester (L-
NAME) resulted in an increase of the MAP and abolished
the difference between transgenic mice and wild-type
littermates. The increase in the MAP (MAP) caused by
L-NAME treatment was greater in transgenic mice than in
non-transgenic controls. There were no differences found
in heart rate (Figure 4b) or mean aortic blood flow (Figure
4c) between transgenic or control mice, with or without
treatment with L-NAME. Consequently, the difference in
MAP can be attributed to a difference in systemic vascu-
lar resistance (Figure 4d). In addition to a lower pressure
in the systemic bed, we also observed a lower mean
pulmonary artery pressure in eNOS-GFPtg mice of 30%
(Figure 4e). We also analyzed the ventricular weights
(normalized to body weight) of the transgenic mice in
comparison with controls. No differences were found
(Figure 4, f and g).
Plasma Cholesterol Levels in eNOS-GFPtg Mice
Finally, we measured levels of plasma cholesterol in
eNOS-GFPtg mice with different genetic backgrounds as
models for variations in plasma cholesterol levels. We
compared wild-type background, heterozygous low-den-
sity lipoprotein receptor-deficient background, which re-
sults in a condition of slight hypercholesterolemia, and
apolipoprotein-E-deficient background, which results in a
condition of more severe hypercholesterolemia. We
found a slight decrease in cholesterol levels in all back-
grounds when comparing eNOS-GFP transgenic animals
with animals without this transgene (Figure 5a). Next, we
analyzed the lipoprotein profile in two of these back-
grounds. In wild-type background, plasma cholesterol is
predominantly found in high-density lipoproteins
(HDL).19 Thus, the cholesterol-lowering observed in
eNOS-GFP transgenic animals is found in HDL (Figure
5b). In apolipoprotein-E-deficient background, however,
plasma cholesterol is present in the atherogenic lipopro-
teins, very low-density lipoproteins (VLDL) and low-den-
Figure 2. Localization of eNOS-GFP in various organs from eNOS-GFPtg
mice visualized by immunohistochemistry using an antibody directed against
human eNOS. a: Heart. b: Liver. c: Kidney. d: Adrenal. Original magnifica-
tions, 400.
In Vivo Expression of eNOS Fused to GFP 1681
AJP October 2003, Vol. 163, No. 4
Figure 3. Localization of eNOS-GFP in various organs from eNOS-GFPtg mice visualized by fluorescence microscopy. a and b: Heart. c and d: Liver. e and f:
Kidney. g and h: Adrenal. Original magnifications: 100 (a,c,e,g) and 400 (b,d,f,h).
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sity lipoproteins (LDL).16 In this background, expression
of eNOS-GFP results in a decrease in both VLDL	LDL
and HDL (Figure 5c).
Discussion
We generated transgenic mice that express human
eNOS in fusion with GFP. To preserve transcriptional
regulation, we used a genomic construct which contains
the intronic sequences as well as the natural flanking
sequences, including the previously identified endothe-
lial enhancer located 4.9 kb upstream of the transcription
initiation site.18 The expression pattern was visualized
either indirectly via immunohistochemistry using antibod-
ies directed against eNOS, or directly via fluorescence
microscopy. Both techniques showed virtually the same
distribution of the eNOS-GFP transgene in a variety of
organs: endothelial cells of smaller and larger vessels in
various organs are positive, while the parenchymal cells
are not. These results indicate that the DNA construct
used for microinjections resulted in expression of the
transgene predominantly, if not exclusively, in endothelial
cells.
The functionality of the eNOS-GFP fusion protein was
demonstrated in two different ways. Using the L-arginine
to L-citrulline conversion assay, it was shown that eNOS
enzyme activity is 30-fold higher in eNOS-GFP trans-
genic animals compared with non-transgenic controls. In
ex vivo measurements with a NO sensor, NO production
Figure 4. Hemodynamics and ventricular weights were measured in control
mice (C) or eNOS-GFPtg mice (Tg) before and after addition of L-NAME. a:
Mean aortic pressure. b: Heart rate. c: Mean aortic blood flow. d: Systemic
vascular resistance. e: Pulmonary artery pressure. f: Ventricular wet weights.
g: Ventricular dry weights. a to d: n  10 (C), n  9 (Tg). e: n  8 (C), n 
6 (Tg). f to g: n  20 (C), n  12 (Tg). *, P  0.05 versus corresponding
controls; †, P  0.05 versus corresponding baseline before addition of
L-NAME; ‡, P  0.05  in C versus  in Tg ( produced by addition of
L-NAME).
Figure 5. a: Plasma cholesterol concentrations of wild-type, LDLR heterozy-
gous knockout (LDLR	/
) and apolipoprotein E homozygous knockout
(ApoE
/
) mice with (Tg) or without (C) the eNOS-GFP transgene. *, P 
0.01 versus controls; **, P  0.001 versus controls. b and c: Fractionation of
lipoproteins by gel filtration of plasma from mice with wild-type background
(b) or apolipoprotein E knockout background (c). Fraction 1–5 contain
VLDL, 6–11 contain LDL, and 12–20 contain HDL.
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by endothelial cells in isolated blood vessels was shown
to be 1.8-fold higher when vessels from eNOS-GFP trans-
genic mice were used.
The apparent discrepancy between these measure-
ments can be explained by the difference between the
methods that were used. In the L-arginine to L-citrulline
conversion assay, a homogenate of aortic tissue was
used. Cofactors and reagents are added to the assay to
optimize the conditions for the enzymatic reaction. There-
fore, the actual measurement represents the maximal
eNOS activity, thereby reflecting the total amount of en-
zyme present. In contrast, the ex vivo measurements with
the NO sensor were performed in intact blood vessels. As
a consequence, the cellular regulation of the activity of
the enzyme is still intact. In this system, the actual NO
production is measured. This is much lower than the
maximal enzymatic activity, probably because post-
translational control of eNOS activity is intact.
In addition, blood pressure measurements showed
that the mean aortic pressure was lower in eNOS-GFP
transgenic animals compared with non-transgenic con-
trols. This is in agreement with findings in other trans-
genic models of eNOS overexpression.16,20 In the latter
models, pulmonary pressures have not been measured.
However, these are expected to be decreased as well, as
the pulmonary vasodilator response following NO inhala-
tion in patients is well known.21,22 Indeed, we found lower
pulmonary pressure in eNOS-GFP transgenic animals
compared with non-transgenic controls.
GFP expression has been used in various transgenic
mouse models and in numerous in vitro studies using
cultured cells. It is generally assumed that the GFP pro-
tein itself does not interfere with any biological function of
other proteins studied. However, specific expression in
cardiomyocytes has been reported to result in hypertro-
phy.23 Although the transgene in our mouse model is
expressed in endothelial cells and not in cardiomyocytes,
we measured the ventricular weights of transgenic and
control mice. No differences were found, demonstrating
that hypertrophy probably does not occur in eNOS-GF-
Ptg mice.
Previously, we generated and studied transgenic
mice overexpressing eNOS without GFP.16 In addition
to a lower blood pressure, these animals displayed a
decrease in plasma levels of cholesterol. Thus, we
measured plasma cholesterol in eNOS-GFP transgenic
mice and found a decrease of 20% compared with
non-transgenic mice (Figure 5a). Plasma cholesterol in
mice is for the larger part in HDL, which is generally
believed to be atheroprotective.19 Therefore, athero-
sclerosis in mouse models is usually studied in a ge-
netic background with increased cholesterol in athero-
genic very low-density lipoproteins (VLDL) and low-
density lipoproteins (LDL). We crossbred eNOS-GFPtg
mice with two of these models. First, we crossbred
them to low-density lipoprotein receptor-deficient
mice, resulting in a background of heterozygous defi-
ciency. This genetic background causes mild hyper-
cholesterolemia.24 In addition, we crossbred the mice
in an apolipoprotein E deficient background, which
causes more severe hypercholesterolemia.16 In both of
these backgrounds, we found that expression of
eNOS-GFP results in lower levels of plasma cholesterol
(Figure 5a). While in wild-type background a reduction
in HDL-cholesterol was found (Figure 5b), the effect in
apolipoprotein E-deficient mice occurred primarily in
the VLDL	LDL cholesterol fraction (Figure 5c). This is
in agreement with our previous work, in which it was
tentatively concluded that this effect contributed to the
anti-atherogenic properties of elevated eNOS expres-
sion.16
The mouse model described in the present study
can be used to study the unusually complex regulation
of eNOS.11,13 Regulation takes place at the transcrip-
tional level,25–27 and is responsive to variations in
shear stress.28,29 In addition, extensive regulation of
eNOS activity at the post-translational level exists.
These pathways are probably also active in the eNOS-
GFPtg mice, as these are most likely responsible for
the remarkable discrepancy between the level of pro-
tein overexpression and the physiological level of NO
production (compare Figure 1, d and e with f). The
post-translational regulatory mechanisms include pro-
tein-protein interactions, some of which affect the sub-
cellular localization of the protein. eNOS is primarily
located in the Golgi complex and in the caveolae in the
plasma membrane, which were shown to be two pools
of active enzyme,14 although others have suggested
that active eNOS is largely restricted to caveolae.30 –32
A number of proteins have been shown to interact with
eNOS and affect its activity. Caveolin, the structural
protein of the caveolae, forms an inhibitory complex
with eNOS,32 for which further evidence was provided
by studies in caveolin-deficient mice.33 On activation
by calcium, calmodulin can activate eNOS by displac-
ing it from caveolin.34,35 Another protein that binds to
eNOS and subsequently activates it is heat shock pro-
tein 90.36 The latter protein appears to play a role in the
caveolin-calmodulin regulatory complex.37 Recently
identified proteins that interact with eNOS have been
termed NOSIP and NOSTRIN.38,39 The functions of
these proteins have not been established yet. Still an-
other way of post-translational regulation of eNOS ac-
tivity is protein modification, like palmitoylation and
myristoylation,40,41 or phosphorylation, especially of
the serine at position 1177 (human eNOS).42,43
The eNOS-GFPtg mice described in the present study
are particularly suitable for studying various aspects of
the complex regulation of eNOS activity. Subcellular lo-
calization under various conditions or dynamic changes
in this pattern on various stimuli can be studied, as well
as interactions with other proteins or with the cytoskele-
ton.44 Valuable information has been achieved by study-
ing expression of eNOS-GFP cDNA in transfected
cells.45,46 Our model also allows ex vivo and in vivo stud-
ies, including real-time imaging by intravital microscopy.
These type of studies will be useful to further assess the
impact of eNOS activity in processes like reactivity to
variations in shear stress or angiogenesis under condi-
tions of ischemia or in tumor growth.
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